Skip to main content
. Author manuscript; available in PMC: 2021 Jan 22.
Published in final edited form as: Nature. 2020 Jul 22;583(7818):845–851. doi: 10.1038/s41586-020-2513-4

Extended Data Figure 4. Phenotypic differences between B-ALL cells driven by oncogenic STAT5 or ERK reflect developmental rewiring during early B-cell development.

Extended Data Figure 4.

a, Murine B-cell precursors, Stat5-driven B-ALL cells, BCR-ABL1-driven B-ALL cells and NRAS-driven B-ALL cells were analyzed by flow cytometry for CD43, IL7R, VpreB, IgM, Ig-κ, IgD and CD21 surface expression. Normal CD19+ B-cell precursors from bone marrow cells and CD19+ spleen B-cells from wild-type mice were used as reference. Shown are representative FACS plots from 3 independent biological replicates. b, For STAT5-driven B-ALL cases (n=26) and ERK-driven B-ALL cases (n=67), mRNA levels of IGHM, IGLV, BCL6 and IKZF1 were studied from microarray results and associated with clinical outcome (COG P9906) at the time of diagnosis. Patients in each group were segregated into two based on higher vs lower than median mRNA levels for each of the four genes. Overall survival and relapse-free survival for the Kaplan-Meier plots are shown to compare relapse-free or overall survival for the higher- vs lower than median groups for IGHM, IGLV, BCL6 and IKZF1 as potential outcome predictors. Mantel-Cox log-rank test (two-sided) was used to determine statistical significance.